InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Monopar Therapeutics

MNPR Clue Score35
United States Fiscal year ends December CIK 0001645469
$78.96 -5.98% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $78.96 +1,594.42% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 19 Dec 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−1.2Net income−1.2Fiscal year 2017Revenue0.0Operating income−16.6Net income−16.6Fiscal year 2018Revenue0.0Operating income−3.3Net income−3.2Fiscal year 2019Revenue0.0Operating income−4.3Net income−4.2Fiscal year 2020Operating income−6.5Net income−6.3Fiscal year 2021Operating income−9.1Net income−9.1Fiscal year 2022Operating income−10.5Net income−10.5Fiscal year 2023Operating income−8.8Net income−8.4Fiscal year 2024Revenue0.0Operating income−16.2Net income−15.6Fiscal year 2025Revenue0.0Operating income−16.7Net income−13.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 0.0 0.0 n/a n/a n/a n/a 0.0 0.0
Growth
Operating income −1.2 −16.6 −3.3 −4.3 −6.5 −9.1 −10.5 −8.8 −16.2 −16.7
Net income −1.2 −16.6 −3.2 −4.2 −6.3 −9.1 −10.5 −8.4 −15.6 −13.7
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2016Operating cash flow−1.2Fiscal year 2017Operating cash flow−2.6Fiscal year 2018Operating cash flow−2.7Fiscal year 2019Operating cash flow−3.0Fiscal year 2020Operating cash flow−4.7Fiscal year 2021Operating cash flow−7.3Fiscal year 2022Operating cash flow−7.2Fiscal year 2023Operating cash flow−7.9Fiscal year 2024Operating cash flow−6.4Buybacks0.0Fiscal year 2025Operating cash flow−12.2Buybacks−35.0
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.2 −2.6 −2.7 −3.0 −4.7 −7.3 −7.2 −7.9 −6.4 −12.2
Buybacks n/a n/a n/a n/a n/a n/a n/a n/a 0.0 −35.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash2.1Shareholders’ equity2.8Fiscal year 2017Cash9.0Shareholders’ equity9.6Fiscal year 2018Cash6.9Shareholders’ equity6.9Fiscal year 2019Cash13.2Shareholders’ equity12.6Fiscal year 2020Cash16.7Shareholders’ equity15.7Fiscal year 2021Cash20.3Shareholders’ equity18.9Fiscal year 2022Cash8.2Shareholders’ equity10.1Fiscal year 2023Cash7.3Shareholders’ equity5.6Fiscal year 2024Cash45.8Shareholders’ equity55.0Fiscal year 2025Cash61.8Shareholders’ equity137.8
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 2.1 9.0 6.9 13.2 16.7 20.3 8.2 7.3 45.8 61.8
Shareholders’ equity 2.8 9.6 6.9 12.6 15.7 18.9 10.1 5.6 55.0 137.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−1.2 −2.6 −2.7 −3.0 −4.7 −7.3 −7.2 −7.9 −6.4 −12.2
Growth
Investment
n/a n/a n/a n/a n/a 0.0 −4.9 4.9 −14.3 −63.5
Financing
1.3 9.5 −0.2 9.3 8.2 10.9 0.0 2.0 59.3 91.6
n/a n/a n/a n/a n/a n/a n/a n/a 0.0 −35.0

Capital expenditure, dividends and buybacks are shown as money out, so negative.